Direct-acting antivirals and risk of hepatocellular carcinoma: from genetic signature to metabolic risk factors

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the second leading cause of cancer-related death. Hepatitis C virus and mainly hepatitis C virus-related cirrhosis is the chief risk factor for HCC. Many direct-acting antivirals are available for the eradication of hepatitis C virus with remarkable results in terms of virological response and with optimal safety profile. Notably, some authors have suggested that viral eradication due to these new drugs might favor both occurrence and recurrence of HCC. The exact biological mechanisms of carcinogenesis in this specific setting have not been well identified, but it has been suggested that adjustments in immune surveillance and increase in vascular endothelial growth factor expression could have a chief role. Remarkably, after publication of many large studies and meta-analyses, we can affirm that there is no increased risk on a population basis. Nonetheless, on an individual basis, sustained virological response due to direct-acting antivirals may facilitate HCC onset in some specific subgroups of patients. Among them, we could point out patients with activated neoangiogenesis but also subjects with particularly severe metabolic imbalance.

Keywords

Direct-acting antivirals / hepatocellular carcinoma / carcinogenesis

References

[1] Ferlay J,Dikshit R,Mathers C.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012..Int J Cancer2015;136:E359-86

[2] Beste LA,Green PK,Ross D.Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013..Gastroenterology2015;149:1471-82

[3] D’Ambrosio R,Colombo M.Hepatocellular carcinoma in patients with a sustained response to anti-hepatitis C therapy..Int J Mol Sci2015;16:19698-712 PMCID:PMC4581320

[4] Fattovich G,Zagni I.Hepatocellular carcinoma in cirrhosis: incidence and risk factors..Gastroenterology2004;127:S35-50

[5] Thein HH,Dore GJ.Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression..Hepatology2008;48:418-31

[6] Sangiovanni A,Fasani P,Ronchi G.Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance..Gastroenterology2004;126:1005-14

[7] Yano H,Haramaki M,Takayama A.Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines..Hepatology1999;29:1708-17

[8] Simmons B,Heath K,Hill A.Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response..Clin Infect Dis2015;61:730-40 PMCID:PMC4530725

[9] Conteduca V,Russi S,Dammacco F.Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents..J Infect2014;68:1-20

[10] Sandmann L,Manns MP.Treatment of chronic hepatitis C: efficacy, side effects and complications..Visc Med2019;35:161-70 PMCID:PMC6616049

[11] Conti F,Scuteri A,Bolondi L.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals..J Hepatol2016;65:727-33

[12] Reig M,Perelló C,Ribeiro A.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon free therapy..J Hepatol2016;65:719-26

[13] Kozbial K,Schwarzer R,Al-Zoairy R.Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment..J Hepatol2016;65:856-8

[14] Rinaldi L,Coppola N,Imparato M.Hepatocellular carcinoma in HCV cirrhosis after viral clearance with direct acting antiviral therapy: preliminary evidence and possible meanings..WCRJ2016;3:e748

[15] Ioannou GN,Berry K.HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma..J Hepatol2017; PMCID:PMC5837901

[16] ANRS collaborative study group on hepatocellular carcinomaLack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts..J Hepatol2016;65:734-40

[17] Ikeda K,Kobayashi M,Fujiyama S.Direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma..Dig Dis Sci2017;62:2932-42

[18] Grandhe S.Occurrence and recurrence of hepatocellular carcinoma after successful direct-acting antiviral therapy for patients with chronic hepatitis C virus infection..Gastroenterol Hepatol2017;13:421-5 PMCID:PMC5572972

[19] Villani R,Bellanti F,Piscazzi A.DAAs rapidly reduce inflammation but increase serum VEGF Level: a rationale for tumor risk during anti-HCV treatment..PLoS One2016;11:e0167934 PMCID:PMC5172554

[20] El Kassas M,Salaheldin M,Eltabbakh M.Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C infected Egyptian cohort: a comparative analysis..J Viral Hepat2018;25:623-30

[21] Saraiya N,Rich NE,Parikh ND.Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct acting antiviral therapy..Aliment Pharmacol Ther2018;48:127-37 PMCID:PMC6019180

[22] Waziry R,Grebely J,Law M.Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, metaanalyses, and meta-regression..J Hepatol2017;67:1204-12

[23] Singh S,Loke YK.Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma: a systematic review and meta-analysis..Frontline Gastroenterol2018;9:262-70 PMCID:PMC6145438

[24] Rutledge SM,Li DK.No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis..Hepatoma Res2019;5:31 PMCID:PMC6709867

[25] Singal AG,Mehta N,Pillai A.Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma..Gastroenterology2019;157:1253-63.e2 PMCID:PMC6815711

[26] Van der Meer AJ,Feld JJ,Dufour JF.Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis..JAMA2012;308:2584-93

[27] Ogawa E,Kajiwara E,Nomura H.Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study..J Hepatol2013;58:495-501

[28] Morgan RL,Smith BD,Pitasi M.Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies..Ann Intern Med2013;158:329-37

[29] Faillaci F,Critelli R,Schepis F.Liver angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after hepatitis C virus direct-acting antivirals..Hepatology2018;68:1010-24 PMCID:PMC6175123

[30] Villa E,Lei B,Cammà C.Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study..Gut2016;65:861-9

[31] Ravaioli F,Brillanti S,Mazzella G.Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals..Dig Liver Dis2018;50:573-9

[32] Ioannou GN,Green PK,Tapper EB.Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores..Gastroenterology2019;157:1264-78 PMCID:PMC6815714

[33] El-Serag HB.Obesity and hepatocellular carcinoma: hype and reality..Hepatology2014;60:779-81

[34] El-Serag HB,Richardson P.Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection..Hepatology2016;64:130-7 PMCID:PMC4917456

[35] Kanwal F,Ilyas J,El-Serag HB.HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV..Hepatology2014;60:98-105 PMCID:PMC4689301

[36] Kanwal F,Jiao L,Sansgiry S.Genetic variants in interleukin-28B are associated with diabetes and diabetes-related complications in patients with chronic hepatitis C virus infection..Dig Dis Sci2015;60:2030-7

[37] Nahon P,Bourcier V,Marcellin P.Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs..Gastroenterology2018;155:1436-50

[38] Ndrepepa G,Kastrati A.Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease..Clin Chim Acta2018;476:130-8

[39] Taliani G,Nigro G,Boddi V.Serum concentration of gammaGT is a surrogate marker of hepatic TNF-alpha mRNA expression in chronic hepatitis C..Clin Immunol2002;105:279-85

[40] Ghany MG.Hepatitis C guidance 2019 update: american association for the study of liver diseases-infectious diseases society of america recommendations for testing, managing, and treating hepatitis C virus infection..Hepatology2020;71:686-721

[41] He S,Alavi M,Hajarizadeh B.Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma..Aliment Pharmacol Ther2020;51:34-52

[42] Casadei Gardini A,Conti F,Vukotic R.Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals..Dig Liver Dis2019;51:681-8